Semax and Selank together: the evidence

The question comes up constantly in nootropic forums. If you are using both Semax and Selank, should you take them at the same moment or space them apart? The honest answer is that nobody knows, because no published study has given both peptides to the same person. The closest the literature gets is a 2020 Russian brain-imaging study that gave 52 healthy volunteers either Semax, or Selank, or placebo, in separate groups^[1]. There is no combination arm anywhere in the record, so there is no timing evidence to report.

What each peptide is, and what its own record looks like

Semax is a short synthetic peptide built from a fragment of adrenocorticotropic hormone. It was developed in Russia and the human work on it is concentrated in stroke recovery. The most-cited clinical study is Gusev and colleagues in 2018, which followed 110 patients (43 men, 67 women, mean age 58.0 plus or minus 9.7 years) through rehabilitation and reported that what the authors call the standard regimen, two 10-day courses at 6,000 micrograms a day separated by a 20-day interval, raised plasma brain-derived neurotrophic factor and improved motor performance and Barthel index scores^[2]. Our Semax page walks through that literature in full.

Selank is a synthetic analogue of tuftsin, an immune-signalling peptide, and its clinical record is anxiolytic rather than cognitive. Zozulia and colleagues studied 62 patients with generalised anxiety disorder and neurasthenia in 2008, comparing Selank in 30 patients against the benzodiazepine medazepam in 32. They reported comparable anxiolytic effects, with additional antiasthenic and psychostimulant effects for Selank^[3]. Two compounds, two different clinical questions, two separate bodies of work.

Nobody has tested the two together

The 2020 study by Panikratova and colleagues is the only human work we found that examined both compounds inside one protocol, and it deliberately kept them apart. Fifty-two healthy participants had resting-state fMRI scans before, then 5 and 20 minutes after, what the paper describes as the injection of either Semax, or Selank, or placebo, and the analysis compared the groups against each other^[1]. That design tells you something about how Semax and Selank each shift amygdala connectivity. It tells you nothing about what happens when both are present at once.

This is not because the researchers behind these peptides avoid combination work. Medvedev and colleagues ran exactly that kind of study in 2015, giving 30 patients the benzodiazepine phenazepam alone and 40 patients phenazepam with Selank added, and reported that the combined arm reached its effect earlier and carried fewer unwanted effects such as attention and memory impairment, asthenia and sedation^[4]. The appetite for combination studies is there. The specific Semax plus Selank pairing has simply never been run.

A 2026 narrative review of therapeutic peptides in gerontology, which includes Semax among the neuroprotection-class compounds it assesses, names combination therapy effects as one of the open knowledge gaps across this whole category^[5]. That is a fair description of where things stand.

The route in the question is not the route in the studies

Forum questions about this pair are usually about subcutaneous injection, and that is worth pausing on, because subcutaneous is not the route the clinical record rests on. The Gusev stroke work dosed Semax intranasally^[2]. The Panikratova imaging study describes an injection^[1]. We found no published subcutaneous dose-finding work for either peptide, which means anyone injecting is already outside the studied protocol before the timing question is even asked. The route and dosing detail we have for Semax comes from Russian intranasal practice, not from injection studies.

What the evidence base actually is

Three features of this literature matter more than any single result. The sample sizes are small: 110, 62, 70 and 52 across the four human studies cited here. The publication venue is narrow, with three of the four appearing in Russian-language journals. And the authorship overlaps heavily. N. F. Myasoedov appears as an author on the Selank anxiety trial^[3], the phenazepam combination study^[4] and the imaging study^[1].

None of that makes the findings wrong. It does mean the usual check has not happened: independent replication outside the originating research network is what turns a promising signal into something a regulator will act on, and for these two peptides it has not arrived. The EU Clinical Trials Register holds no registered trial for either compound^[6]. The 2026 review groups Semax with the non-approved peptides that, in its own words, lack long-term safety data and systematic validation^[5].

Where this leaves the timing question

We are not going to answer it with a schedule, because answering it would mean inventing one. A same-time-versus-spaced recommendation implies a known interaction: shared clearance, competing targets, an additive or a blunting effect. None of that has been measured for this pair in humans. Any specific timing advice you find online is somebody's guess carrying more confidence than the data behind it.

What you can do is read each compound on its own record. The Semax page covers the Russian clinical work, the rodent mechanism studies and the regulatory position outside Russia. The supply questions that apply to BPC-157 and ipamorelin apply here too. Without a batch certificate of analysis you do not know what is in the vial, and that uncertainty sits underneath every other question, including timing.

If you are considering either peptide, that is a conversation for a clinician who knows your medical history, not a thread. This article is educational and journalistic and is not medical advice.